TQB3454: on track to be China's first domestic IDH1 inhibitor for IDH1-mutant biliary tract cancer — so why won't it be won or lost in the lab?

To understand TQB3454, first understand the company behind it. In 2025, Sino Biopharmaceutical achieved revenue of RMB 31.83 billion, basic profit attributable to shareholders of RMB 4.54 billion, R&D expenses of RMB 5.87 billion, and innovative product revenue of RMB 15.22 billion. Oncology has long been the group's largest therapeutic area (about RMB 10.73 billion in 2024, about 37.2% of group revenue), with dozens of innovative drugs in development, nearly half of them in oncology. This is not a biotech kept alive by financing, but a self-funding commercialization machine with a thick portfolio.

The core product supporting this oncology map is the multi-target small molecule anlotinib (Focus V) — an oral anti-angiogenic drug covering non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, thyroid cancer and other tumor types, with cumulative five-year sales exceeding RMB 20 billion and single-year sales at one point breaking the RMB 3 billion level. Its significance lies not only in sales, but in the fact that through it CTTQ built a sales and medical promotion team that reaches deep into medical oncology, hepatobiliary surgery and GI oncology departments, and a clinical and expert network covering leading tertiary hospitals.

Now the asset itself. TQB3454 is an oral mutant IDH1 inhibitor: IDH1 (R132) mutations, common in biliary tract cancer and other tumors, cause cells to produce an "oncometabolite" called 2-hydroxyglutarate (2-HG), disrupting DNA and histone methylation and locking cell differentiation. TQB3454 inhibits the mutant enzyme to lower 2-HG, putting tumor cells back on track toward normal differentiation. Its lead indication is advanced IDH1-mutant biliary tract cancer after failure of gemcitabine- and fluoropyrimidine-based regimens (the trial registration also mentions and/or platinum) — i.e. previously treated later-line patients (not simply equivalent to a uniform "second line").

Why is this later-line population worth pursuing? Because they are almost at a "dead end". Biliary tract cancer is already among the GI cancers with the worst prognosis; early symptoms are insidious and most diagnoses are at an advanced stage; after progression on a gemcitabine-based first-line regimen (nowadays usually with immunotherapy added), later-line chemotherapy has very low objective response rates and median survival is often only a few months. For the subset carrying IDH1 mutations, there was previously no specifically approved targeted drug available in China. This is the vacuum TQB3454 wants to fill — not squeezing one more into a crowded lane, but filling a corner "with a clear molecular marker, yet long short of drugs". The unmet need is real; there is no inflation here.

Honesty is needed here: this mechanism was not invented by CTTQ. The first to make the IDH1-inhibitor-in-biliary-tract-cancer road work globally was Servier/Agios's ivosidenib (brand name Tibsovo). So at the mechanism level TQB3454 is a "follower"; its differentiation cannot rely on a "new mechanism", only on three things: the quality of its data, its accessibility in China, and its price.

The yardstick for TQB3454's efficacy is ivosidenib's global Phase 3 study ClarIDHy. This randomized, double-blind, placebo-controlled study produced the following results:

There is a key detail in reading ClarIDHy: its intention-to-treat overall survival did not reach statistical significance (HR 0.79). The reason is that many placebo patients crossed over to ivosidenib after progression, diluting the between-group difference; the protocol therefore pre-specified an RPSFT sensitivity analysis to estimate the scenario "had crossover not occurred", which after adjustment showed a significant overall survival benefit (HR 0.49). This is a pre-specified analytical method accepted by regulators — but the presence of crossover does make interpretation of the overall survival endpoint call for more caution.

TQB3454's potential differentiation may land precisely here. It has been officially disclosed that under placebo control, at the interim analysis, both PFS and OS crossed the protocol's pre-specified superiority boundaries. If its overall survival benefit was obtained directly under "cleaner" conditions without large-scale crossover contamination, then in terms of data quality it has a chance to tell a more complete story than ClarIDHy.

On safety, settings need to be distinguished: differentiation syndrome is the hallmark risk of IDH inhibitors in myeloid malignancies such as acute myeloid leukemia, and was not a main issue in the biliary tract cancer study (ClarIDHy). In the solid tumor setting of biliary tract cancer, what deserves more attention is QTc interval prolongation, GI reactions, anemia, ascites, bilirubin abnormalities and drug–drug interactions. Officially, TQB3454's safety profile is consistent with known risks with no new signals — good news, but after launch routine ECG monitoring and liver function and electrolyte management will still be needed under the risk management plan, a management hurdle in primary-care settings.

If the efficacy data are yet to be revealed, China registration progress is a certain advantage TQB3454 already has in the bag. Its timeline is as follows:

The value of this path lies in three facts "already in hand": both Breakthrough Therapy Designation and priority review have been obtained, with review resources clearly tilted toward it; this is a purely domestic Phase 3 in Chinese patients, with no ethnic extrapolation and no need for an additional bridging trial; and it is a standard randomized, double-blind, placebo-controlled study with overall survival as the primary endpoint (the trial registration records OS as primary and PFS as secondary), the highest tier of evidence for oncology drugs, rather than the "debt" model of accelerated approval on a single-arm study with confirmation owed after launch.

The choice of control arm is defensible given the specific prior-treatment conditions: the ABC-06 study established FOLFOX as one standard later-line option, but most TQB3454 enrollees had already received fluoropyrimidines and even platinum, leaving no further standard regimen for them; a placebo control is both ethical and consistent with the global ClarIDHy approach. Moreover, guidelines already list IDH1 inhibitors as an option in the later-line population — market education has already been done for it by the originator.

Now to the core tension of this asset. First, how small the market is: a study covering 188 cancer registries nationwide estimated about 61,900 new cases of intrahepatic cholangiocarcinoma (iCCA) in China in 2015, with an age-standardized incidence of about 2.7 per 100,000 (the previously circulated figure of around 7.45 per 100,000 more likely came from individual regional registries and cannot represent the whole country). And IDH1 mutations are mainly enriched in intrahepatic cholangiocarcinoma, at a mutation rate of about 13%–25% (one expert consensus gives IDH1 mutations at about 25.3%). Filtering layer by layer through "intrahepatic cholangiocarcinoma × IDH1-positive × previously treated later-line × actually tested", the patients who can really use the drug form a niche market well below ten thousand people.

For a biotech, such a small market might not support a dedicated sales team; but for a giant like Sino Biopharmaceutical the logic is completely different — TQB3454 doesn't need to support a new team; it just needs to "ride along". The coverage of medical oncology, hepatobiliary and GI oncology departments that anlotinib has cultivated for years already reaches the same prescribers; for the same medical affairs and medical promotion team, the marginal cost of adding an IDH1 product is extremely low. That is the real meaning of "a commercial platform amplifies single-product returns": the absolute market ceiling of a small indication is not high, but because the platform is shared and marginal cost is extremely low, its return on investment may actually be very attractive.

This funnel shows two things. First, the absolute market ceiling is not high, and expecting it to become the next multi-billion product is unrealistic. Second, the bottom layer of the funnel, "detected", is the most easily overlooked yet the most fatal — every layer before it is the objective distribution of disease; only the last layer can be changed through commercial action. Whoever raises testing penetration expands their own accessible market. That is also why, for this drug, the value of "marketing" and "medical" is in some sense no less than that of "clinical".

Then there is price. As an oral small molecule, TQB3454 has very low manufacturing costs, giving it room that other modalities can only envy: even after entering the NRDL with a negotiated price cut of 50%–70%, it can still make a gross profit. For a small indication, "trading price for volume and rapid hospital listing" is often a smarter choice than "holding a high price and ramping slowly", and a low-cost structure makes that road affordable.

Biliary tract cancer has become a hot testing ground for precision therapy in recent years, but many people easily confuse the competition in this market. The key point: different molecular subtypes use different targeted drugs, which do not directly compete for patients.

• First line: the mainstream is immunotherapy plus chemotherapy (e.g. durvalumab, based on the TOPAZ-1 study), and recently Akeso's ivonescimab received Breakthrough Therapy Designation in first-line biliary tract cancer. This is a battlefield TQB3454 cannot reach.
• Second-line precision subtypes: FGFR2 fusion patients use FGFR inhibitors (pemigatinib and HUTCHMED's fanregratinib, among others, approved or under review in China); HER2-positive patients have seen clear progress — China approved zanidatamab in May 2025 for previously treated HER2 IHC3+ advanced biliary tract cancer; and IDH1-mutant patients are TQB3454's home turf.

In other words, the FGFR and HER2 drugs look like they are "also second-line biliary tract cancer", but they occupy separate segments that don't interfere with TQB3454. TQB3454's only real head-on rivals are the handful of other IDH1 inhibitors.

And on this narrow IDH1 track, there is only one real rival — and it is already on Chinese shelves

This is the most critical passage in the article. There is more than one domestic peer — besides Haihe Biopharma's HH2301, there are IDH1 programs such as MT-001 and KY-100001 in early development; but no other domestic program is close to the registration stage, and none constitutes a near-term threat. The real rival is the originator ivosidenib (Tibsovo), and its situation is very delicate:

There is also a pricing subtlety hidden here. As a leukemia drug, ivosidenib has long been priced in the Chinese market and has been through market access battles; once it moves into biliary tract cancer, the originator's pricing anchor and channels are ready-made. If TQB3454 wants to build a defensive line with the "domestic + NRDL" combination punch, it must complete its first moves on price and hospital access before the originator files for biliary tract cancer — negotiating after the originator formally enters would weaken its initiative. In other words, speed is not only about "who is approved first", but also "who locks in the minds of payers and hospitals first".

So the real meaning of TQB3454's "China's first" becomes clear: it has a chance to become the first IDH1 inhibitor approved for the "biliary tract cancer indication" in the Chinese market — because the originator is currently approved in China only for leukemia, not yet for biliary tract cancer. But this "first" window is uncertain: if Servier chooses in the future to file a supplemental application for biliary tract cancer, then with its marketed foundation and ready-made global data it could come from behind and erase this "first". This is a potential scenario requiring continuous vigilance (there is currently no evidence of a filing), and the dark cloud most worth guarding against over the whole asset.

Compared with the uncertainties of efficacy and competition, manufacturing and supply is the least worrying part of this drug. It is an oral small-molecule tablet: mature process scale-up, a low share of manufacturing cost (usually 5%–10%), room-temperature storage and transport, no cold chain, no delivery device, and certainly none of the "one patient, one batch" delivery challenges of cell therapy. CTTQ has large-scale in-house API and formulation capacity, supply continuity is essentially not a risk, and dependence on CDMOs is very low.

The only question mark is global supply chain capability — but this is exactly consistent with its positioning of "China as the main battlefield": since it is not focused on going global in the near term, there is no need to roll out multi-regional overseas registration and overseas GMP systems specifically for this drug. This is not a weakness; it is a trade-off.

An asset's fate often depends on its ranking in the company portfolio. A sober judgment is needed on TQB3454: it is a "precision gap-filling" asset, not the next anlotinib-level blockbuster. Oncology is the group's largest segment (on the order of RMB 10.7 billion), with as many as 39 oncology drugs in development; in such a thick portfolio, a niche small-indication product naturally has to compete with big products and big indications for promotional resources and management attention.

The good side: there is no cannibalization within the portfolio — the group has no second asset with the same target and tumor type, and TQB3454 is complementary to products like anlotinib rather than competitive. For the platform it is "incremental ride-along", not "internal competition for food". The real risk is not internal portfolio conflict but priority: when promotional resources are limited, will a small product with a market in the thousands be pushed to the back under the halo of big products and be under-invested? This is where management needs to make an active commitment.

As for global value — frankly, going global is not this drug's main line. The global IDH1 market in biliary tract cancer is already held by the originator; if TQB3454 forced its way abroad, it would need separate multi-regional trials and would struggle to differentiate on data, so the return on investment is not worthwhile. With reference to the roughly US$50 million deal size for ivosidenib's China rights, the out-licensing valuation of such assets is inherently limited. Honestly defining it as a "China platform, domestic-demand-driven" asset is far more truthful than forcing a global story, and gives better guidance for resource allocation.

TQB3454 is a very "typical" precision asset of a large Chinese pharma: the mechanism isn't new, but execution is on point; the market isn't big, but the leverage is attractive; the data may not be bad, but they have to be realized through speed and accessibility. Its strongest side is the certainty of China registration and the mature commercial network behind it; its weakest side is limited global value and a low ceiling; and the dark cloud most worth guarding against overhead remains the multinational rival that already has the same class of originator drug on Chinese shelves and has the conditions to file for biliary tract cancer (there is currently no evidence of a filing).

So back to the opening line — it really won't be won or lost in the lab. Phase 3 has already been won; the next battle is about who writes this indication into a Chinese label first, who first enables primary-care physicians to detect patients, and who first gets the drug into hospitals. This is a race of speed, accessibility and commercial execution — precisely the game Sino Biopharmaceutical is best at.